ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. was established in 2014 with a vision of Overcoming Resistance In Cancer. The company focuses on targeting innate, acquired, and bypass resistance mechanisms in oncology, aiming to develop and commercialize innovative therapies that address cancer resistance, including by making existing therapies work better and longer. Its lead product candidate, ORIC-101, a glucocorticoid receptor antagonist, is in Phase 1b trials. The company has also initiated a Phase 3 study of rinzimetostat in combination with darolutamide in metastatic prostate cancer, and is enrolling Phase 1b studies of rinzimetostat in prostate cancer and enozertinib in NSCLC patients with EGFR exon 20 mutations.

ORIC Pharmaceuticals was established in 2014 with a bold vision of Overcoming Resistance In Cancer. The company focuses on targeting innate, acquired, and bypass resistance mechanisms in oncology. Its lead product candidate, ORIC-101, a glucocorticoid receptor antagonist, is in Phase 1b trials. The company has initiated a Phase 3 study of rinzimetostat in combination with darolutamide in metastatic prostate cancer patients previously treated with abiraterone, and is enrolling Phase 1b studies of rinzimetostat in prostate cancer and enozertinib in NSCLC patients with EGFR exon 20 mutations.

Targeting resistance mechanisms to improve patients' lives.

• 2021.11.10

  Reported2021.11.10

  Carl L. Gordon resigns from ORIC's board[4]Carl L. Gordon辞去ORIC董事会职务biospace.com

  ORIC stated that Carl L. Gordon resigned from its board concurrent with Angie You's appointment.

• 2021.11.10

  Reported2021.11.10

  ORIC appoints Angie You to its board[4]Carl L. Gordon辞去ORIC董事会职务biospace.com

  ORIC Pharmaceuticals announced the appointment of Angie You, Ph.D., to its board of directors.

• 2020.04.02

  Reported2020.04.02

  ORIC Pharmaceuticals appoints Christian V. Kuhlen as General Counsel[5]ORIC Pharmaceuticals任命Christian V. Kuhlen为总法律顾问prnewswire.com

  ORIC Pharmaceuticals announced that Christian V. Kuhlen had been named General Counsel and would serve on its executive leadership team.

Read more

1. 1HOME - ORIC Pharmaceuticalsoricpharma.com
2. 2About - ORIC Pharmaceuticalsoricpharma.com
3. 3ORIC Pharmaceuticals, Inc. (United States)wikidata.org
4. 4Carl L. Gordon辞去ORIC董事会职务biospace.com
5. 5ORIC Pharmaceuticals任命Christian V. Kuhlen为总法律顾问prnewswire.com